AnaptysBio, Inc. manages royalty-focused financial collaborations tied to Jemperli with GSK and imsidolimab with Vanda. Following the completed separation of First Tracks Biotherapeutics, the company’s recurring updates center on royalty asset management, collaboration economics, contractual rights, stock repurchase activity, and governance changes.
News about ANAB also includes developments involving imsidolimab, a licensed antibody asset being developed by Vanda, and legal or contractual matters related to the Jemperli collaboration. Company announcements have additionally covered board and finance leadership appointments and the corporate transition from a biopharma operations business to a streamlined royalty management model.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.